The Food and Drug Administration granted de novo approval to Modius Spero, marking it the world’s first neuromodulation device authorized to ...
The FDA granted de novo approval for a neuromodulation device to treat symptoms associated with post-traumatic stress ...
Patients with PTSD show higher rates of chronic overlapping pain conditions in both populations with commercial insurance and Medicaid.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results